Zach Berman MD
@ZTBerman
Meliorist and Monozukuri , #Bernedoodle Dad, Interventional Oncologist @UCSDHealth
Is Y90 Dosimetry Adequately Taught During IR Fellowship?-- IRs reflect on their prior education in dosimetry and share their strategies for equipping trainees in this realm of practice Stream the full episode here: youtu.be/mtknCLeDAXY Enroll in our free BackTable+ course…
This is huge. Congrats to @sio_central on showing what a society can do to push the field forward. Looking forward to the future of Interventional Oncology!
The @SIO_Central ACCLAIM Trial has officially reached its enrollment target. This study prospectively validates a reproducible technical endpoint in the treatment of colorectal liver metastases. Thank you, @bostonsci, NeuWave Medical, and @VarianMedSys. conta.cc/4kTif6B
How do experts balance aggressive tumor dosing with liver safety when treating HCC with Y90? Drs. Zach Berman & Tyler Sandow join Dr. Kavi Krishnasamy to break down real HCC cases, from large central tumors, portal vein invasion, and multifocal lesions. Tune in to glean insight…
Glad to see our MultiD collaboration gaining traction. #PASTIME - @ucsd_ir @UCSD_ObGyn @rupalparikh90 @SIRspecialists
Placenta Accreta Spectrum (PAS) is a high-risk condition requiring coordinated care. This SIR MSC WIR infographic outlines the PASTIME approach as an IR model within a multidisciplinary framework #WIRSIR
🔥Our Recent Publication Highlighting the Importance of 💉Biopsy for HCC🔥 Even in the era of LI-RADS molecular profiling is/will be important for deciding 💊. doi.org/10.1016/j.ejra… @ucsd_ir @UCSDRadRes @SIO_Central @_backtable @SIRspecialists @BeauToskichMD
Further confirmation of the high ORR and DoR of TARE for HCC. I suspect today marks the death of BSA and the beginning of the era of personalized dosimetry.
We're proud to announce that SIR-Spheres® is now the only FDA approved radioembolization therapy for both unresectable HCC & colorectal cancer liver metastases in the U.S. Read the full announcement: bit.ly/4ktbRTs SIR-Spheres® Safety Info: bit.ly/3XEwjIo
Editor's Choice! 📖 Read this interesting commentary on the paper of Tahir et al, underlying the benefits of personalized dosimetry for radioembolization but also the limitations of the current methods. link.springer.com/article/10.100…
In this discussion, the multidisciplinary panel focuses on a case of a non-cirrhotic patient with a solitary #HCC lesion that falls outside of ablation criteria. Stream the entire episode, with all case studies and imaging here: youtu.be/3DLVodvSGFU Enroll in our free…
Coming off of a great SIR, presenting our robotic ablation experience, here is a nice robotic MWA case for two obliquely placed probes covering an irregular CRC met with margin confirmation. @ucsd_ir @SIRspecialists @SIO_Central @QuantumSurgical @_backtable @_backtableONC
Congratulations to our Best Traditional Poster and the Best Educational Exhibit presentation winners! Your research and work are amazing, and we're thrilled to recognize them at #SIR25NASH!
I am incredibly interested to see the results! Nice work NW team. Going to be a great session.
Preview one of SIR's Abstracts of the Year! Hear from @SamMouli on the Frontier Study: Preliminary Results of Safety and Feasibility of Yttrium-90 TheraSphere in Recurrent Glioblastoma. Read here: irq.sirweb.org/sirtoday/2025-… #TheraSphereGBM #Y90 #FRONTIERstudy #SIR2025…
Congrats to our new #radres! Welcome to @UCSDRadRes and @UCSDImaging!!! Thank you to our PD's and admins for your tireless efforts!
Congratulations to all on the match! We can't wait to meet our new UCSD IR and DR residents! #MatchDay2025
#Y90 radiation segmentectomy is now a recommended ablative modality by the AASLD for unresectable BCLC A #HCC or as a bridge to transplant. journals.lww.com/hep/fulltext/2… Post local therapy complete pathologic necrosis (CPN) of tumor has been associated with significantly improved post…
Had a great time making this and learned a ton! Def recommend a listen.
A recent hepatocellular carcinoma (HCC) @_backtableONC episode tackles key cases, from multifocal HCC to post-transplant metastasis. Watch now with MCC's @ZTBerman & Dr. Adam Burgoyne: bit.ly/4ivLH2d. 🎙️
Here's a CASE-BASED episode with our #HCC Tumor Board, covering diff scenarios & how to think thru each one: youtu.be/3DLVodvSGFU We discuss: - Moderate Sized Lesions - Multifocal HCC - Dominant Lesion with Portal Hypertension - Ruptured Solitary vs Multifocal Lesions -…
🔥Hot off the press🔥 Voxel-Based tumor dose matters for HCC - particularly D95. tinyurl.com/mpk8485m Now to explore this for big tumors?🤔 @ucsd_ir @uclaVIR @bsc_io @SirtexMedical @SIO_Central @SIRspecialists @_backtable
Today on BackTable: @ZTBerman hosts an all-star panel of IRs who provide insights on their journeys to building their interventional oncology practices in different settings Watch the episode: youtu.be/X-aJzq15hKY #ONC8 @SidpadiaIR @bayouteazy @kavikrishVIR @kevinburns
No MAA for hepatocellular carcinoma <3 cm treated with Y90 radiation segmentectomy expedites care, reduces the number of procedures, is valued by patients, and should be the new SOC for this therapy. 🧩 @SIRspecialists @cirsesociety @JVIRmedia @CVIR_Journal
Our initial prospective series on single-session no MAA radiation segmentectomy for small, solitary #HCC 💥 demonstrated a favorable safety profile, outcomes, & patient satisfaction. Streamlining treatment in select patients is feasible! @BeauToskichMD sciencedirect.com/science/articl…
Today on @_backtableONC : We explore the "grey zone" of treatment goals for #HCC patients with intermediate-stage/BCLC-B disease- youtu.be/MloiijDyTYo?si… Awesome insights from @kiremagarciamd @ZTBerman @SDhandMD @UCSDRadRes @OchsnerHealth #ONC5